Researchers have conducted a study, published in Current Pharmaceutical Analysis, which utilized computer models to investigate the properties of compounds found in aloe vera and their potential interaction with brain enzymes. The study found that beta-sitosterol exhibited the strongest affinity for two enzymes responsible for breaking down acetylcholine, a neurotransmitter associated with neuronal communication and decreased levels of which are linked to Alzheimer's disease.
Researchers have identified a compound with potential therapeutic properties, suggesting it may inhibit enzymes and preserve acetylcholine, a key neurotransmitter involved in nerve cell communication. According to a study press release, acetylcholine levels are significantly reduced in Alzheimer's patients, contributing to memory loss and cognitive decline.
The findings do not provide conclusive evidence that aloe vera or its supplements have a positive impact on memory or disease treatment.
Researchers have relied on computer simulations to develop the work, with further validation required through laboratory experiments and human clinical trials.
A spokesperson for the Alzheimer's Association has cautioned that inhibiting certain enzymes does not prevent the loss or damage of brain cells. Individuals experiencing cognitive changes are advised to seek guidance from a qualified healthcare professional.
Further analysis of the compound revealed it to be effectively absorbed by the body and demonstrated low toxicity in therapeutic concentrations, suggesting potential for future medical applications.
A recent study found that aloe vera contains beta-sitosterol, although the concentration varies significantly depending on the plant part, extraction method, and analysis technique. The study specifically examined a lyophilized aloe gel extract, which contained approximately 1.6 milligrams of beta-sitosterol per gram of dry extract, representing about 93% of the total identified phytosterols, with a concentration of 1,604.5 parts per million.
The gel's composition primarily consisting of water renders it challenging to determine a precise value for its fresh state. Historical estimates suggest that the gel's microcomponents comprise approximately 0.001% of its total composition, which in turn implies even lower concentrations of beta-sitosterol. However, these estimates do not provide a direct or specific measurement of the compound's concentration.
Research indicates that consuming aloe vera in the form of a drink or gel typically yields minimal amounts of beta-sitosterol, which can vary significantly depending on the product's concentration. To achieve the studied doses of beta-sitosterol, supplements or fortified foods are generally utilized, rather than aloe vera gel.
Limited research indicates that beta-sitosterol does not appear to interact significantly with commonly prescribed Alzheimer's medications, including donepezil, rivastigmine, galantamine, and memantine. Nevertheless, due to the scarcity of available evidence, individuals considering beta-sitosterol as a supplement are advised to consult with their doctor or pharmacist to assess potential interactions.
Important precautions :
Individuals with Alzheimer's disease who are taking multiple medications, including anticoagulants, statins, and supplements, as well as those with heart rhythm issues, should consult their doctor before adding beta-sitosterol to their regimen. While there is currently no documented interaction between beta-sitosterol and these medications, further review of the individual's treatment schedule, dosage, and specific needs is recommended to ensure safe and effective use.
Potential readers may also find the following information relevant to their interests.
Research has highlighted the complex relationship between attention deficit and dementia, often leading to blurred distinctions between the two conditions. A recent study has also established a correlation between insomnia and an increased risk of developing dementia, as well as other mental health disorders. Furthermore, a lesser-known condition known as type 3 diabetes has been identified as a potential risk factor, with a need to differentiate it from more common forms of the disease.
